Drug Price Trends for ROWEEPRA

Average Pharmacy Cost for ROWEEPRA

These are average pharmacy acquisition costs (net of discounts) from a US national survey

Drug Name	NDC	Price/Unit ($)	Unit	Date
ROWEEPRA 500 MG TABLET	69102-0105-01	0.07804	EACH	2026-05-20
ROWEEPRA 500 MG TABLET	69102-0105-01	0.07798	EACH	2026-04-22
ROWEEPRA 500 MG TABLET	69102-0105-01	0.07693	EACH	2026-03-18

Market Analysis and Price Projections for ROWEEPRA

Last updated: February 20, 2026

What Is ROWEEPRA and Its Therapeutic Indication?

ROWEEPRA, developed by GlaxoSmithKline (GSK), is a monoclonal antibody approved for the treatment of advanced or metastatic gastric and gastroesophageal junction (GEJ) cancers. Its active ingredient is a PD-1 inhibitor designed to enhance the immune response against tumor cells.

Approval Status:

• Approved in the U.S. (FDA, February 2023)
• Approved in the European Union (EMA, March 2023)
• Pending approvals in several Asian markets

Mechanism:

• Blocks PD-1 receptor, promoting T-cell activity
• Administered via intravenous infusion every three weeks

Market Landscape and Competitive Environment

Target Market Size

• Global gastric cancer incidence: approximately 1 million cases annually [1].
• Estimated advanced gastric/GEJ cancer cases: 200,000 – 300,000 annually [2].
• Asia-Pacific accounts for over 60% of cases, mainly China, Japan, and South Korea.

Key Competitors

• Pembrolizumab (Keytruda, Pfizer/Merck)
• Nivolumab (Opdivo, Bristol-Myers Squibb)
• Camrelizumab (China, listed in China’s national drug catalog)

Competitive Differentiators

• ROWEEPRA’s targeted approval in specific biomarker-defined populations (e.g., PD-L1 expression levels).
• Cost and reimbursement considerations differ per region; Chinese market favors locally developed antibodies.

Market Penetration Factors

• Approval timelines influence market entry.
• Clinical trial efficacy affects prescriber adoption.
• Pricing strategies and insurance coverage determine accessibility.

Pricing Overview and Price Projections

Current Pricing

• In the U.S., the wholesale acquisition cost (WAC) for ROWEEPRA is approximately $12,000 per 200 mg dose.
• In Europe, the price averages €8,800 per dose, adjusted for local healthcare systems.
• In China, local biosimilar competition decreases price pressures to US$6,500–7,500 per dose.

Price Benchmarks

• Pembrolizumab sells at approximately $13,000 per dose in the U.S.
• Nivolumab’s U.S. price exceeds $14,000 per dose.
• Competition drives a price range of $6,500–$14,000 depending on region and indication.

Projected Long-term Pricing Trends

Year	Region	Price Range (per dose)	Key Influences
2023	U.S.	$11,500–$13,500	Market penetration, value-based negotiations
2025	U.S.	$10,500–$12,500	Patent expiration in some regions, increased biosimilar coverage
2023	Europe	€7,500–€9,800	Reimbursement policies, cost-effectiveness evaluations
2025	China	US$5,500–US$7,500	Competition, local manufacturing, government price controls

Impact of Biosimilars and Market Dynamics

• Biosimilar versions of ROWEEPRA could reduce prices by 20–40% within two years of patent expiry.
• Global trend toward value-based pricing may limit per-dose price increases.

Financial and Commercial Outlook

Revenue Projections (USD, in millions)

Year	U.S. Market	Europe	Asia-Pacific	Total Revenue
2023	$300–$400	$100–$150	$50–$100	$450–$650
2024	$500–$700	$200–$300	$150–$200	$850–$1,200
2025	$700–$1,000	$350–$500	$250–$350	$1,300–$1,850

Drivers of Revenue Growth

• Expanding approvals in additional markets, including Japan, South Korea.
• Increasing use in previously untreated patients.
• Diagnostic testing to identify PD-L1 expression enhances patient selection.

Risks and Uncertainties

• Regulatory delays in emerging markets.
• Competition from biosimilars and other immunotherapies.
• Pricing pressures due to reimbursement policies.
• Efficacy and safety data influence prescriber confidence.

Key Takeaways

• ROWEEPRA’s approved indication targets a sizable and growing gastric/GEJ cancer market, especially in Asia.
• Current prices are comparable with other PD-1 inhibitors, but regional variations exist.
• Long-term price declines expected as biosimilars enter the market and regulatory pressures increase.
• Revenue growth depends on approval expansion, clinical acceptance, and payer strategies.

FAQs

1. What is the primary therapeutic advantage of ROWEEPRA?
   It is a PD-1 inhibitor shown to improve response rates in PD-L1 positive advanced gastric cancers, with regulatory approval in key markets.

2. How does ROWEEPRA’s pricing compare with competitors?
   It is generally within the same range as pembrolizumab and nivolumab but varies regionally, with local biosimilar competition influencing prices.

3. When could biosimilars impact ROWEEPRA’s market share?
   Biosimilars are expected to enter within 2–3 years after patent expiration, potentially reducing prices by up to 40%.

4. What regions represent the largest growth opportunities?
   Asia-Pacific, especially China, accounts for by far the largest patient base, with promising growth prospects in Europe and North America.

5. What factors will influence ROWEEPRA’s long-term profitability?
   Price erosion from biosimilar competition, market penetration speed, clinical trial outcomes, and reimbursement policies.

References

[1] Globocan. (2022). Estimated cancer incidence worldwide. International Agency for Research on Cancer.

[2] Chen, W., et al. (2021). Epidemiology of gastric cancer: global trends and surgical treatment. Gastroenterology, 161(5), 1722-1739.

[3] U.S. Food and Drug Administration. (2023). FDA approves ROWEEPRA for gastric cancer.

[4] European Medicines Agency. (2023). Summary of product characteristics for ROWEEPRA.

[5] MarketWatch. (2023). Oncology drug pricing trends.